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Abstract
Background: Lymphatic filariasis (LF) affects more than 120 million people worldwide. Efforts to
eliminate this disease require sustained community participation. This study explores community
valuation of LF elimination efforts by estimating household and community willingness to pay
(WTP) for the prevention of transmission and treatment of filarial lymphedema in the community
of Leogane, Haiti.
Methods: A contingent valuation survey was used to assess individual WTP for specific prevention
and treatment interventions. A 2-dimensional Monte Carlo simulation was developed to estimate
confidence limits in mean WTP and to generate a distribution of WTP for the community,
accounting for uncertainty in regression coefficients and variability within the population.
Results: Mean WTP was estimated to be $5.57/month/household (95% CL: $4.76, $6.72) to
prevent disease transmission, and $491/yr (95% CL: $377, $662) for treatment of lymphedema for
one person. Based on the estimated distributions, 7% and 39% of households were not willing to
pay for prevention and treatment, respectively.
Conclusions: These results suggest that the majority of the community places a positive value on
both prevention and treatment of LF. Mean WTP provides a useful monetary estimate of overall
societal benefit of LF prevention and treatment programs. However, for interventions which
require broad and sustained community participation, the lower end of the distribution of WTP
has additional implications. Cost recovery policies may result in inadequate participation and longer
program duration.
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Background
Lymphatic filariasis, a mosquito-transmitted parasitic dis-
ease, affects an estimated 120 million people worldwide,
causing lymphatic dysfunction in virtually all those
infected and recurrent acute adenolymphangitis (ADL),
hydrocele, and lymphedema in millions of affected per-
sons. Infection with the parasite results in damage to lym-
phatic vessels, leading to swelling of the limbs and
genitals and painful bacterial infections. As the swelling
progresses, it becomes difficult for individuals to carry out
their household and job-related activities [1]. The disfig-
urement caused by the disease can also lead to social
stigma and difficulty in fulfilling social roles. The burden
of the disease includes medical expenses, lost productiv-
ity, value of familial assistance, and the value associated
with diminished social function and quality of life [2].
Following the 1997 declaration by the World Health
Assembly and the subsequent drug donations by SmithK-
line Beecham (now GlaxoSmithKline) and Merck & Co.
Inc., global and local efforts to eliminate LF as a public
health problem were intensified. These efforts are directed
toward interrupting transmission of the parasite and pro-
viding treatment for people with clinical filarial disease.
In selecting and allocating resources, local and national
decision makers along with international donors need
information on the value that filariasis-endemic commu-
nities place on prevention and treatment services. Several
studies have estimated the economic value of certain
aspects of disease burden, particularly the cost of medical
attention and the productivity losses associated with the
disease [1,4-6]. However anthropological studies of com-
munities with endemic LF suggest that the more intangi-
ble benefits of preventing and treating filarial disease (e.g.
reduced social stigma) may provide a greater contribution
to social wellbeing [7]. This study uses a contingent valu-
ation method to estimate the economic value of both the
direct and intangible benefits of preventing and treating
lymphatic filariasis in a Haitian community. Contingent
valuation studies are typically used to characterize the
mean or total value placed on an improvement in health
within a community, and compare it to the costs of the
improvement. Here the approach also is used to examine
distribution of household willingness to pay (WTP) for
interventions within the community and the expected
impact on participation rates, to provide a more complete
measure of the benefits of these projects.
Methods
Lymphatic filariasis is endemic to parts of Haiti, including
the town of Leogane and its surrounding communities.
The descriptions of the treatment and prevention pro-
grams in the valuation exercises are modeled after projects
conducted in the Leogane area. The treatment interven-
tion includes the management of lymphedema and pre-
vention of adenolymphangitis (ADLs) through improved
hygiene, skin care, and physical measures, such as eleva-
tion and movement. Two prevention strategies can be
used to interrupt transmission of LF, either regular use of
table salt fortified with diethylcarbamazine (DEC) [8] or
mass administration with a 2-drug combination: DEC
plus albendazole or ivermectin plus albendazole [9]. Both
kill the microfilaria produced by adult parasites, prevent-
ing further transmission. For this study DEC-fortified salt
was the intervention used in the valuation exercise.
Survey Instrument
Individual WTP was elicited using an in-person survey
conducted between November and December 1997, prior
to the implementation of a DEC-fortified salt distribution
program [8]. The survey was translated into Haitian Cre-
ole and was developed and pre-tested with the help of
bilingual (Haitian Creole and English) residents of
Leogane. The survey's four sections included information
on demographics, knowledge and attitudes about LF, and
two dichotomous choice WTP exercises (one for a preven-
tion intervention and the other for a lymphedema treat-
ment intervention). Demographic information included
sex, age, household size, monthly household cash
income, and type of house construction (cement, wood,
or thatch). The latter was used as an index of wealth. The
questions regarding knowledge and attitudes towards
filariasis were based on earlier anthropological work on
community perceptions of the disease in Leogane [7]. The
section included questions on familiarity with the differ-
ent disease-related conditions, perceived risk of being
infected with the filarial parasite, and the respondents'
beliefs about transmission of the disease.
In the prevention exercise, individuals were asked about
WTP for the prevention of infection in the entire house-
hold. Respondents were asked whether they would be
willing to pay a predetermined amount to purchase DEC-
fortified salt for their family, in order to prevent new filar-
ial infections among family members. The respondents
replied "yes" or "no" to the questions. Dichotomous
choice questions are recommended over open-ended
questions that ask individuals directly how much they are
willing to pay [10]. Although the latter are statistically eas-
ier to analyze, they are often difficult for respondents to
answer and may not result in individuals reporting their
true maximum willingness to pay.
The valuation exercise for the treatment intervention fol-
lowed the same basic format as that used to value preven-
tion. Respondents were asked to imagine that they had
lymphedema. A hypothetical condition was described,
along with a course of treatment and expected improve-
ment in health status from the treatment. Improvement
was described as including cessation of acute attacks,Filaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/2
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reduced swelling, and improvement in mobility. The
amount of time each day required for treatment was also
described. Respondents were then asked whether they
would pay different predetermined amounts for the sup-
plies required for the lymphedema treatment (e.g., soap,
towel, basin, antiseptics). The treatment exercise elicited
WTP for treatment of one individual. In both exercises,
bid amounts were presented in Haitian gourdes. They are
converted to U.S. dollars in the results presented here.
For both exercises, each respondent was offered a single
bid amount. The bids for each respondent were chosen
randomly from 5 and 4 possible values for the prevention
and treatment interventions, respectively. Following the
general approach outlined by Alberini [11], bids were
selected using limited data from pilot testing. Bid
amounts were intended to cover the expected range of true
underlying WTP values of respondents based on data
from pilot testing with 25 individuals. Using a single bid
value for all respondents can result in inefficient and
biased parameter estimates [12].
The study area has an estimated population of approxi-
mately 20,000 individuals. The survey was administered
to a random sample of adults in the town of Leogane and
its immediate surroundings. Sampling was based on the
division of area into four geographically defined regions:
two in central Leogane (east and west) and two immedi-
ately adjacent communities (one to the north and one to
the south). Within each area houses were selected by start-
ing at a random corner and choosing every third house on
the street. When the end of the street was reached, the
process was begun on an adjacent street. Sampling within
each area continued until 150 sample households were
identified and one adult household member was inter-
viewed. The study protocol and data collection instru-
ment were approved by the human subjects protection
committees of the Centers for Disease Control and Pre-
vention and the Hospital Ste. Croix (Leogane, Haiti).
Data analysis
The data were analyzed from three perspectives: the distri-
bution of household WTP within the community, the
community's total WTP, and the expected participation of
households in the interventions. Data were analyzed in
two stages. In the first stage, data from the survey were
used in two regression models to estimate household
WTP for prevention of infection in the entire household
and treatment of one individual, based on household
characteristics. Willingness to pay for treatment (WTPt)
and prevention (WTPp) interventions were each estimated
with a single bound probit model using the responses to
the valuation question. The probit model estimates the
likelihood that the household would be willing to pay dif-
ferent amounts for the interventions, rather than estimat-
ing a single WTP for each household. The shape and
location of the likelihood function depend on several
household characteristics.
The model for WTPt included sex, age, income, whether
someone in the household had lymphedema or
hydrocele, accurate knowledge of the causes of filariasis,
household construction type (cement vs. wood/thatch) as
a proxy for wealth, and the starting bid. The model for
WTPp included these same variables plus two additional
ones: household size and perceived risk. The model was
specified as
Pr {'yes'} = Φ(α + βA),
where Φ is the cumulative distribution function of the
standard normal distribution, α and β are the estimated
regression parameters, and A is the vector of household
characteristics described above. The LIMDEP econometric
software package was used to obtain the maximum likeli-
hood estimates for the regression parameters [13]. The
order in which the WTP questions were presented did not
influence valuation responses in the initial model and this
was not included in the final model.
In the second stage of the data analysis the results of the
regression model were used to estimate the distribution of
household WTP for prevention and treatment within the
community (rather than that of individual households).
Several approaches can be used to estimate population
mean willingness to pay from the estimated household
likelihood functions. The traditional approach of estimat-
ing WTP for each respondent in the sample to estimate the
mean and distribution was not used. This approach was
not used in effort to adjust for potential selection bias in
our sample. Because a disproportionate number of
respondents were women and approximately 35% did not
provide their income, to adjust for potential selection bias
in our sample a Monte Carlo simulation was used to esti-
mate the mean and the distribution of household WTP,
using Crystal Ball software [14]. The simulation model
captures the variability within the population by repeat-
edly calculating the function estimated in the regression,
using different combinations of household characteristics
(income, number of members, etc.). This approach
allowed us to use the expected gender distribution in the
community and an estimated income distribution (based
on those who responded), in order to adjust for potential
biases within our sample. The model also incorporates
uncertainty in the individual regression coefficient
estimates.
Variability in respondent and household attributes was
characterized by fitting distributions to the different inde-
pendent variables (income, household members, age,Filaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/2
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etc.), using the survey data. Continuous distributions
were fit for income, age, and number of household mem-
bers using Crystal Ball's distribution fitting procedures.
Discrete distributions were used for categorical data (e.g.
sex, knowledge, house type). Uncertainty in the regression
coefficients was characterized based on the estimated var-
iances and covariances of the parameters estimated in the
regression model.
A 2-dimensional Monte Carlo simulation model was used
to separate variability in household characteristics from
uncertainty in the estimated coefficients of the determi-
nants of WTP. For both prevention and treatment, the
model operates by first selecting a random set of regres-
sion coefficients from their respective distributions. Hold-
ing these coefficient values constant, the model then
randomly selects 1,000 combinations of household char-
acteristics, based on the distribution of each. These are
used to describe a likelihood distribution (based on the
probit regression results) from which each household's
WTP is estimated. A new set of regression coefficients is
then selected and the process is repeated (250 iterations).
The result provides a description of the distribution of
household WTP for prevention and treatment within the
community, and confidence intervals for these estimates.
The model was also run allowing all variables to change
simultaneously to develop an overall estimate of the dis-
tribution (using 100,000 iterations), including variability
within the population and uncertainty regarding the fitted
distribution.
Participation rates for both interventions were then esti-
mated by calculating the percentage of the population
willing to pay more than a series of different amounts. For
both interventions, mean household WTP was estimated
among the entire population and those willing to pay a
positive amount. For the prevention intervention, com-
munity willingness to pay was estimated based on esti-
mates of population, household size, percentage of the
population willing to participate, and mean WTP.
Results
A total of 583 useable surveys were collected, of which
346 respondents reported monthly household income.
The latter surveys were used to estimate WTP, while all
surveys were used for descriptive statistics and to fit
Distribution Of Willingness To Pay For Individual Lymphedema Treatment In Leogane, Haiti ($/Year) Figure 1
Distribution Of Willingness To Pay For Individual Lymphedema Treatment In Leogane, Haiti ($/Year)
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distributions for age, income, and household size (Table
1). Approximately 71% of respondents were women,
presumably due to their greater likelihood of being at
home during the times when the surveys were conducted
(Table 1). The mean reported monthly household income
was 624 Haitian Gourdes, (US$35, [18 Gourdes = US$1
in 1999]). The majority of respondents reported knowing
someone with lymphedema or hydrocele (84% and 76%
respectively). Approximately 20% reported having a fam-
ily member with lymphedema or hydrocele. Half of the
respondents did not have an opinion as to how likely they
were to get filariasis. However, 62% of those who did
described it as likely or very likely. Only 22% of the peo-
ple surveyed correctly identified potential sources of filar-
ial infection. Fifty-two percent of respondents identified
magical powder as a cause of lymphedema. Differences in
respondent familiarity and knowledge about filariasis did
not significantly differ between men and women.
Regression model results
Estimation results for prevention and treatment interven-
tions are shown in Table 2. These parameters reflect the
impact of a change in each of the variables on the proba-
bility of a 'yes' response. For each household, these
parameters define a cumulative distribution function
based on the household's characteristics, representing the
likelihood that the household is willing to pay a given
amount. Willingness to pay for treatment was positively
affected by income, and negatively affected by age, a belief
in a magical etiology, living in a wood or thatch home,
having someone in the household with lymphedema or
hydrocele, and appropriate knowledge about the causes of
filariasis. Willingness to pay for prevention was positively
affected by income, and negatively affected by living in a
wood or thatch home and having someone in the house-
hold with lymphedema or hydrocele.
Figure 1 shows the estimated overall distribution of
household WTP for treatment within the community
based on the Monte Carlo simulation. Approximately
61% [95% C.I.: 52–69%] of the population would be
willing to pay some positive amount for lymphedema
treatment. Among those individuals who would be
willing to pay for treatment, the mean was $805 [$724 –
$959]/year. This represents the maximum amount of
income the household would be willing to give up for ces-
sation of acute attacks, reduced swelling, and improved
social function associated with treatment of lymphedema
for one year as presented in the survey scenario. Since
individuals with negative WTP would choose not to par-
ticipate in such a program, the value of the program to
them is zero. Assuming a WTP of zero for these individu-
als, results in a mean WTP of $491/yr (95% CL: $377 –
$662) for the community as a whole.
For LF prevention the mean WTP for all households was
$5.57 per month [$4.76 – $6.72]. This represents the
maximum amount of income the household would be
willing to give up each month to eliminate the risk of any
household member developing LF. This mean monthly
household WTP is equivalent to $12.15 annually per per-
son, assuming 5.5 people per household. Figure 2 shows
the estimated distribution of household WTP for preven-
tion within the community. Approximately 93% [88–
Table 1: Demographic And Other Characteristics Of Survey Respondents – Leogane, Haiti
Demographic Characteristics N Mean Fitted Distribution Information
Distribution Goodness of Fit*
Age 583 39.1 Gamma, Location 0.31, Scale 1.74, Shape 2.97 Chi-Square 87.63 K-S 0.043 A-D 1.50
Monthly Income (Gourdes)** 346 624.0 Weibull, Location -1.03, Scale 417.28, Shape 0.60 Chi-Square 351.11 K-S 0.205 A-D 19.87
Household Size 583 5.5 Gamma, Location 15.98, Scale 11.55, Shape 2.00 Chi-Square 1067.81 K-S 0.0867 A-D 4.52
NP e r c e n t
Sex (percent female) 583 71.4
House Construction 583
Thatch 4.5
Wood 51.1
Cement 44.4
Knowledge and Attitudes
Knowledge of causes 583 22.3
Belief in magical etiology 583 52.1
High perceived risk (risky or very risky) 274 37.2
Familiarity
Know someone with lymphedema 581 84
Know someone with hydrocele 580 76
Family member with lymphedema 577 19.2
Family member with hydrocele 580 10.7
*Distributions fit using Crystal Ball software (Decisioneering, 2000). K-S and A-D refer to the Kolmogorov-Smirnov and Anderson-Darling 
goodness-of-fit tests, respectively. **18 Gourdes =US$1 in 1999Filaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/2
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97%] of the population would be willing to pay some
positive amount for DEC-fortified salt. Assuming a WTP
of zero for other households, the mean was $5.77 per
month, with a 95% confidence interval of $4.91 – $7.01.
The annual economic value of preventing LF is estimated
based on the expected number of households willing to
pay for the intervention and the mean WTP for these
households. Given a total population of 20,000 individu-
als and an average of 5.5 individuals per household, total
annual monetary value of preventing lymphatic filariasis
is approximately $252,000 per year. This is the amount
the community would be willing to pay each year for pre-
vention and hence it estimates the annual value of the
program benefits. This does not include the value of
reduced likelihood of infection for individuals who
choose not to participate in the intervention but may
nonetheless benefit by the reduced risk resulting from a
community-wide program.
Estimated rates of participation for different levels of indi-
vidual cost are shown in Figure 3. Potential individual
costs for the DEC salt intervention would include any
increase in the price of table salt resulting from the fortifi-
cation program. Figure 4 shows the influence of income,
house type, and whether a family member has lymphe-
dema or hydrocele on expected participation rates
(assuming no costs to the household).
Discussion
Willingness to pay studies are usually used to estimate the
economic value of the burden created by a disease or the
benefit of reducing that burden as a result of a specific
intervention. Although no studies have directly estimated
the medical costs or productivity losses from filariasis in
this community, the estimated WTP for LF prevention in
this community ($252,000 / year) is likely to exceed
actual medical expenses and productivity losses. The WTP
values estimated in this study reflect the value of avoided
pain, suffering, and reduced social functioning, as well as
any expected medical expense savings or lost earnings.
The monetary value of improved health associated with
an intervention, when combined with other benefit meas-
ures, can be compared to the costs of the intervention in a
cost-benefit analysis. Estimating the costs of LF treatment
and prevention programs is beyond the scope of this
paper. However, the estimated annual value of $12 per
person greatly exceeds initial estimates of the annual per
capita costs of mass treatment with anti-filarial drugs. Esti-
mates from the first three years of mass drug administra-
tion in Leogane, Haiti with DEC and albendazole suggest
an annual cost of $1–2 per person [15]. These initial cost
estimates are within the wide range of costs ($0.05 – $3)
in studies published elsewhere [16,17]. This suggests that
programs to interrupt LF transmission in Haiti are likely to
have very high net value, with the monetary value of ben-
efits exceeding costs. Similarly, the mean WTP for
lymphedema treatment of $805 per year greatly exceeds
the actual annual costs of clinic-based treatment of indi-
Table 2: Single Bounded Probit Model Maximum Likelihood Estimates
Variable Treatment Prevention
Name Explanation Coefficient S.E. P Coefficient S.E. P=
Intercept 2.3831 0.408 0.0001 2.5192 0.454 0.0001
Bid Gourdes -0.0001 0.00001 0.0001 -0.0169 0.0024 0.0001
Income Gourdes/month 0.0004 0.0001 0.0001 0.0004 0.0002 0.0116
Sex (0 = female, 1 = male) -0.0562 0.178 0.7517 -0.0473 0.186 0.7993
Age Years -0.0184 0.006 0.0012 -0.0083 0.006 0.1443
House Type (0 = cement, 1 = wood or thatch) -0.6615 0.145 0.0001 -0.4318 0.149 0.0039
Knowledge Correctly identify causes of filariasis (0 
= yes, 1 = no)
-0.5014 0.188 0.0077 -0.0983 0.199 0.6214
Familiarity Family member with lymphedema or 
hydrocele (0 = no, 1 = yes)
-0.4476 0.181 0.0133 -0.3865 0.197 0.0498
Magic Belief in magic etiology of lymphedema 
(0 = no, 1 = yes)
-0.5692 0.163 0.0005 -0.0124 0.170 0.9420
Household 
Number
Number of people living in household 0.0014 0.025 0.9559
Perceived Risk 0 = not or somewhat risky, 1 = risky or 
very risky
0.3283 0.216 0.1283
Note: The probit model describes the likelihood that a household with specific characteristics would be willing to pay different amounts, rather than 
predicting a single deterministic WTP valueFilaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/2
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viduals with lymphedema in this community, estimated
at $22–78 per person depending on the stage of disease
(S. Kanjilal, personal communication, 2003).
Respondents' knowledge and/or attitudes regarding
filariasis affected willingness to pay for treatment and pre-
vention. However the results do not necessarily indicate
that improved information through health education will
increase participation. It was initially expected that indi-
viduals who identified magical powders as a source of
lymphedema would be willing to pay less for prevention
or treatment interventions which they may see as ineffec-
tive. WTP for prevention was not influenced by beliefs
about etiology. However WTP for treatment was
negatively influenced by both the belief in magical etiol-
ogy and correct knowledge about the mechanisms of filar-
ial infection. A trend toward higher WTP for prevention
was observed among people who perceived themselves to
be at higher risk of getting LF. Although the result was not
statistically significant, it may suggest that health educa-
tion efforts that focus on informing individuals about dis-
ease risks and the opportunity for prevention and
treatment may be more effective than those aimed at
improving knowledge about the biology or causes of LF.
Individuals' familiarity with lymphedema or hydrocele
(whether they or a family member have one of the condi-
tions) significantly negatively affected WTP for treatment
and prevention. This finding is consistent with valuation
studies for other health conditions [18]. Having the con-
dition (or having a family member with it) may lead to
coping mechanisms and increased acceptance, which in
turn reduce an individual's willingness to pay to treat the
condition. In the case of treatment, an alternative hypoth-
esis may be that individuals with lymphedema may be
more cognizant of the immediate financial constraints on
paying for treatment, or they may have felt that the prices
asked about were not 'fair', given their assessment or
knowledge of the actual costs of the treatment services.
Another factor may be that they do not believe that the
treatment would be effective. Individuals who already
have filarial lymphedema also may consider it too late to
prevent it.
Distribution Of Household Willingness To Pay For LF Prevention In Leogane, Haiti ($/Month) Figure 2
Distribution Of Household Willingness To Pay For LF Prevention In Leogane, Haiti ($/Month)
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As expected, household income positively affected esti-
mates of mean WTP for both lymphedema treatment and
LF prevention. Willingness-to-pay studies often restrict
WTP estimates to be less than reported income, given that
households cannot expect to be willing to pay more than
their actual income [12]. In this study we did not
artificially restrict WTP to be less than reported income.
For some households estimated WTP for lymphedema
treatment exceeded their reported income. However this
may not actually represent a violation of the logical
restrictions on WTP. Although households may not realis-
tically be able to pay their entire income to prevent LF or
treat lymphedema, there are other resources that contrib-
ute to household ability to pay. Respondents may base
their WTP on past savings or expected future earnings,
rather than their current monthly income (which may be
highly variable). In addition, WTP for treatment and pre-
vention may be strongly influenced by resources of the
extended family (including individuals living and work-
ing abroad). This is supported by the influence of house-
hold construction type (as a proxy for wealth) on WTP
estimates. Having a house constructed with cement (as
opposed to wood or thatch) was positively related to WTP
for both prevention and treatment.
In this study we used a 2-dimensional Monte Carlo model
to estimate the distribution of WTP, reflecting the fact that
some individuals may be willing to pay a great deal to par-
ticipate in programs, while others have negative WTP. This
suggests that even if the interventions were offered free of
charge, they would choose not to participate. Negative
WTP estimates suggest that some people may see the inter-
ventions as ineffective or not worth the individual costs
associated with participating in them, such as the time,
travel, and other costs. It may also reflect a sense of fatal-
ism about their condition [7]. Their participation would
require an incentive or subsidy of some sort, to offset
these costs.
Such a distribution of household willingness to pay may
have important program implications. For lymphedema
treatment, if the cost of the intervention exceeds a house-
hold's WTP, then that household may choose not to par-
ticipate. For example, if the annual cost of treatment were
the equivalent of $100, the model estimates that 45%
Effects of Participant Costs on Estimated Participation in Prevention Activities (simulation results) Figure 3
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Effect of Income, House type, and Household Members with Clinical Disease on Expected Participation in Prevention (simula- tion results) Figure 4
Effect of Income, House type, and Household Members with Clinical Disease on Expected Participation in Prevention (simula-
tion results)
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would choose not to seek treatment, if they had lymphe-
dema. For the majority of those who would choose to par-
ticipate, the value of the service (their WTP) would exceed
the actual cost to them, resulting in a net benefit or
surplus.
For the prevention intervention, the distribution of WTP
has important implications for the ability of the program
to achieve transmission interruption. The distribution
suggests that as the cost of the intervention to households
increases the rate of participation is likely to decline. It is
believed that a minimum coverage level must be sus-
tained for several years in order to interrupt transmission,
although the precise level is unknown and is likely to dif-
fer between settings [19].
For an individual to decide to participate, the value of pre-
vention must be perceived to be at least equal the cost
incurred by participation. For a DEC-fortified salt pro-
gram this could include any additional costs for the forti-
fied salt. Programs that distribute anti-filarial drugs
through mass drug distribution also may introduce costs
to participating individuals. In some countries cost recov-
ery practices are used for similar programs (e.g. onchocer-
ciasis) to cover program costs. Households may encounter
a variety of costs including transportation to distribution
points or lost time from work.
Based on Figure 3, if it is assumed that 80% of households
need to participate in order to interrupt transmission, the
expected cost (or household contribution) for the inter-
vention (e.g. cost recovery fees, transportation costs, or
additional cost of DEC-fortified salt) would have to be
below the 20th percentile of the WTP distribution ($5.09/
person/yr). Above that value, it is estimated that less than
the required 80% would participate. If the actual cost per
household were greater than the appropriate threshold
WTP, then a subsidy may be required to reach the needed
coverage rate. If 90% participation were needed, then the
cost to households would have to be less than $1.53/per-
son/yr. Other factors may also affect participation,
including illness or pregnancy (contraindications to treat-
ment), fear of adverse drug reactions, and not being avail-
able at the time of drug distribution.
Cost recovery policies may provide short-term revenue,
but may also reduce participation levels, leading to the
need for longer intervention periods to interrupt trans-
mission. Policies that introduce other costs to house-
holds, such as the limiting number of drug distribution
posts or not providing medication for adverse reactions
free of charge, may have a similar effect. Reducing these
costs may increase short-term participation, resulting in
lower long-term costs. While cost recovery policies will
almost always result in reduced participation, the conse-
quences may be particularly important for LF elimination
and other programs that require very high levels of
participation.
Subsidies, whether financial or in the form of other health
services, may be useful in increasing participation, and
decreasing long-term program costs. The anthelminthic
benefit resulting from co-administration of albendazole
with DEC or ivermectin can be viewed as such a subsidy.
Efforts to improve participation in these ways or through
educational campaigns may be particularly important in
specific settings – including poor communities (low
income or lower quality housing) and households of indi-
viduals with clinical disease (Figure 4).
While WTP estimates capture many of the components of
disease burden and program impact, the method may
miss other societal benefits from treatment and preven-
tion programs. For example, other individuals who travel
into the region might be willing to pay for protection dur-
ing short visits. For prevention activities, our WTP esti-
mates do not capture the benefit to future generations
who would no longer be at risk (only the value that these
current residents put on future benefits to others). For
treatment, we may not completely capture benefits to
other household members who may benefit from another
family member's reduced morbidity. Alternative measures
of burden of disease and program benefits include health
metrics (Disability-Adjusted Life Years, Quality-Adjusted
Life Years) and monetary measures of medical costs and
lost productivity. Each of these captures different aspects
of a disease on individuals and society. These approaches
provide burden information which complements WTP
estimates of burden.
Conclusions
The WTP estimates generated in this study expand our
understanding of the economic impact of the disease in
two ways. First, WTP measures provide an estimate of wel-
fare gain that includes changes in morbidity, economic
production, and other intangible values such as social
function. All of these aspects of welfare are affected by
lymphatic filariasis, and should be considered when
assessing the burden of the disease. Second, WTP studies
help identify factors that, if addressed through social
mobilization, subsidies, or other strategies, may improve
program participation rates critical to an elimination goal.
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